WHO Reviewing Data on Bharat Biotech’s Covaxin, Decision on Approval in '24 Hours or So'
3 years, 1 month ago

WHO Reviewing Data on Bharat Biotech’s Covaxin, Decision on Approval in '24 Hours or So'

News 18  

The World Health Organization was reviewing data on Covaxin, India’s indigenously-made vaccine against Covid-19 and will announce a decision on its Emergency Use Listing in “24 hours or so” a spokesperson said. WHO Chief Scientist Soumya Swaminathan had said in a tweet earlier that the technical advisory group at the organisation will meet on October 26 to consider the much-coveted emergency use listing for Covaxin being manufactured by Bharat Biotech. We are aware that many people are waiting for WHO’s recommendation for Covaxin to be included in the #COVID19 Emergency Use Listing, but we cannot cut corners – before recommending a product for emergency use, we must evaluate it thoroughly to make sure it is safe and effective, WHO had said. Ryan said we have to be absolutely sure and it’s really important that we gather all of the necessary information not only on the vaccine itself but on the manufacturing processes and all of that, because we’re recommending to the world that this vaccine is safe, effective and it’s been produced using the highest quality standards.” Further explaining how the WHO technical advisory group works, he said the vaccine manufacturers first of all have to request and respond and say that they want their vaccines to be put for EUL and then provide documentation on the whole process — the efficacy studies and the manufacturing process.

Health World Emergency Data Bharat Ryan 24 Hours Vaccine Advisory Bharat Biotech Covaxin Emergency Use Eul  data  recommendation  hours  world  covaxin  reviewing  vaccines  ryan  health  advisory  bharat  approval  decision  vaccine  emergency  24  biotechs

History of this topic

ICMR got ₹172 cr. from Bharat Biotech for Covaxin: Nadda
4 months, 3 weeks ago

ICMR got ₹172 cr. from Bharat Biotech for Covaxin: Nadda

The Hindu  

The Indian Council of Medical Research has received ₹172 crore as royalty from Bharat Biotech International Limited for jointly developing Covaxin, an indigenously developed vaccine for COVID-19, Union Health Minister J.P. Nadda said, during Question Hour in the Lok Sabha on Friday. Covaxin was jointly developed by ICMR, National Institute of Virology, and Bharat Biotech International Ltd, in two phases. …

Bharat Biotech corrects Covaxin patent to include ICMR, NIV after govt objections: Health Minister
4 months, 3 weeks ago

Bharat Biotech corrects Covaxin patent to include ICMR, NIV after govt objections: Health Minister

New Indian Express  

NEW DELHI: Union health minister J P Nadda on Friday said that Bharat Biotech initially did not mention ICMR and NIV as co-inventors in the patent application for Covaxin and the application was corrected after objections were raised by the government. Covaxin, which was widely used as a Covid vaccine, was jointly developed by the Indian Council of Medical Research, …

The right way to counter a poor Covaxin safety study
4 months, 3 weeks ago

The right way to counter a poor Covaxin safety study

The Hindu  

It took all of five days for the Indian Council of Medical Research to strongly criticise the poor design of the long-term safety study of Covaxin by researchers from the Banaras Hindu University, Varanasi. A publication failure that is glaring Three years after the interim data were posted as a preprint, Bharat Biotech and ICMR are yet to publish any …

Patent filings credit Bharat Biotech as ‘inventor’ of Covaxin, omit ICMR
6 months ago

Patent filings credit Bharat Biotech as ‘inventor’ of Covaxin, omit ICMR

The Hindu  

India’s first indigenously developed coronavirus vaccine, Covaxin, was a joint collaboration between the Indian Council of Medical Research and the Hyderabad-based Bharat Biotech International Limited with intellectual property rights jointly shared between the two organisations. The Minister’s statement said the ICMR would provide a “well characterised” virus strain for vaccine development, the BBIL would develop the final vaccine formulation and, …

1 in 3 Covaxin takers reported adverse events, BHU study claims
7 months, 1 week ago

1 in 3 Covaxin takers reported adverse events, BHU study claims

Hindustan Times  

A one-year follow-up study conducted by researchers at Banaras Hindu University has found that nearly one-third of individuals who received Bharat Biotech's Covaxin reported 'adverse events of special interest'. Read: AstraZeneca Covid vaccine related to another rare but deadly blood clotting disorder Adverse Events of Special Interest: Around 33% of participants reported AESI, with new-onset skin and subcutaneous disorders, general …

BHU study: Over 30 per cent of Covaxin recipients report adverse events
7 months, 1 week ago

BHU study: Over 30 per cent of Covaxin recipients report adverse events

India TV News  

A recent study conducted by researchers at Banaras Hindu University revealed that over 30% of individuals who received Bharat Biotech's Covaxin reported adverse events. The one-year follow-up study, encompassing 926 participants, shed light on the long-term safety of the BBV152 vaccine, with serious adverse events of special interest such as stroke and Guillain-Barre syndrome reported in one per cent of …

AstraZeneca's Covishield Showed Lowest Incidence of Side Effects in India Versus Globally, Says Top Govt Official
7 months, 2 weeks ago

AstraZeneca's Covishield Showed Lowest Incidence of Side Effects in India Versus Globally, Says Top Govt Official

News 18  

AstraZeneca’s vaccine has demonstrated the lowest incidence of side effects in India compared to the global average, a top government official involved in the national roll-out of Covid-19 vaccination told News18. “But only around 50 cases witnessed Thrombosis with Thrombocytopenia Syndrome — a rare side effect caused by the jab — of the 180 crore doses administered against 4 to …

After AstraZeneca covid-19 vax recall worldwide, Serum says it stopped manufacturing jabs in Dec 2021
7 months, 2 weeks ago

After AstraZeneca covid-19 vax recall worldwide, Serum says it stopped manufacturing jabs in Dec 2021

Live Mint  

New Delhi: The Serum Institute of India on Wednesday said it has stopped making and supplying covid-19 vaccine Covishield after AstraZeneca, the British drugmaker that helped develop the vaccine, announced it too was withdrawing its version of the jab worldwide. The development follows the launch of a class action suit in the UK over allegations that the UK vaccine caused …

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine
7 months, 3 weeks ago

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine

Hindustan Times  

Amid reports over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which developed the Covaxin, said in a statement that the vaccine was developed with a "single-minded focus on safety first." It stated that Covaxin was the "only Covid vaccine" in government of India's COVID-19 immunisation program to have conducted efficacy trials in India. "@bharatbiotech announcement - …

Covishield more effective than Covaxin: Study
9 months, 2 weeks ago

Covishield more effective than Covaxin: Study

New Indian Express  

BENGALURU: Covishield vaccine had higher antibody response compared to Covaxin during the pandemic, according to a study by a consortium of 11 institutions led by scientists from the National Centre for Biological Sciences, Bengaluru. In all, 691 people aged between 18 and 45, mostly from Bengaluru and Pune, were part of the study.’Immunogenicity of SARS - CoV-2 vaccines Covaxin and …

With State prod, India can be world leader in vaccines
10 months, 4 weeks ago

With State prod, India can be world leader in vaccines

Hindustan Times  

The World Health Organization activated its incident management support team as part of its emergency response framework on the emergence of a cluster of atypical pneumonia cases emerging from Wuhan, China, on January 1, 2020. India, the dark horse in the vaccine race, did the unexpected and against all odds, approving EUA to two vaccines — “made in India” Covishield …

A new regime: On the Emergency Use Authorisation regime in India and clinical trials
1 year, 5 months ago

A new regime: On the Emergency Use Authorisation regime in India and clinical trials

The Hindu  

Last week, the Drug Controller General of India cleared, under the provisions of ‘emergency use authorisation’, a new mRNA vaccine for COVID-19 developed by Pune-based Gennova Biopharmaceuticals, a pioneer in India in developing mRNA vaccines. More than evidence-based assessment, it was a technicality in India’s ‘New Drugs and Clinical Trials Rules, 2019’ that allowed EUA in India for COVID-19 vaccines. …

India’s Winning Formula: Making Healthcare Affordable and Accessible with PPPs
1 year, 6 months ago

India’s Winning Formula: Making Healthcare Affordable and Accessible with PPPs

News 18  

In the last 75 years, India’s progress as a nation has been both inspiring and impressive. Vaccine PPPs during the Covid-19 pandemic It is during the pandemic that India gained a definite advantage in the global health space, when it administered the first dose of the indigenous Covid-19 vaccine Covaxin, in January 2021. Within a year of the emergence of …

India restarts Covid vaccine production as new infections soar 30% in one day
1 year, 8 months ago

India restarts Covid vaccine production as new infections soar 30% in one day

The Independent  

India is ramping up its vaccine production following a rapid surge in Covid-19 cases driven by a new subvariant dubbed Arcturus. The country recorded 10,158 news Covid cases on Thursday, a 30 per cent surge in one day, according to the federal health ministry data. The company stopped manufacturing Covishield in December 2021 due to dwindling demand and a low …

Bharat Biotech starts dispatching nasal vaccines: Why it’s a big thing for India
1 year, 10 months ago

Bharat Biotech starts dispatching nasal vaccines: Why it’s a big thing for India

Live Mint  

The world's first intranasal heterologous booster dose has begun to be dispatched by Bharat Biotech to hospitals, Executive Chairman Dr. Krishna Ella announced on February 5. He discussed the delivery of vaccines under the bilateral agreement between the Ella Foundation and the UW-Madison Global Health Institute for the establishment of the first-ever UW-Madison One Health Center in India for improving …

Bharat Biotech’s nasal vaccine likely to be launched on Jan 26
1 year, 11 months ago

Bharat Biotech’s nasal vaccine likely to be launched on Jan 26

Hindustan Times  

Bhopal: Bharat Biotech’s nasal Covid-19 vaccine iNCOVACC is expected to be launched on January 26, executive chairman Krishna Ella said at an event on Saturday. “Our nasal vaccine will be officially launched on January 26 on Republic Day,” Ella told students at the Maulana Azad National Institute of Technology in Bhopal, where the India International Science Festival, 2022, is being …

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch
1 year, 11 months ago

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch

Hindustan Times  

Around 250 million Covid vaccines manufactured by two major Hyderabad-based units – Biological E and Bharat Biotech – are ready for dispatch in the market as soon as orders are received. Nearly 200 million Corbevax vaccine of Biological E and 50 million of Bharat Biotech's Covaxin are stockpiled at the moment. Read| Covid drills at hospitals; case count remains low …

Biological E, Bharat Biotech Together Sitting on Stockpile of 250 Million Covid Vaccine Doses
1 year, 11 months ago

Biological E, Bharat Biotech Together Sitting on Stockpile of 250 Million Covid Vaccine Doses

News 18  

Two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together are holding about 250 million doses of Covid-19 vaccines ready to dispatch as and when orders are received. According to respective company sources, Biological E is holding 200 million doses of its Covid-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses …

Covid: Biological E, Bharat Biotech together holding 250 million vaccine doses
1 year, 11 months ago

Covid: Biological E, Bharat Biotech together holding 250 million vaccine doses

Live Mint  

The two major Hyderabad-based vaccine manufacturing units, Biological E and Bharat Biotech, together are holding about 250 million Covid vaccine doses ready to dispatch as and when orders are received, according to news agency PTI. Currently, Biological E is holding 200 million doses of its Covid-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses …

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses
1 year, 11 months ago

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses

India TV News  

As Covid cases are increasing in the country, now focus is back on vaccination drive. According to sources- two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together have about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received. Corbevax and Covaxin stocks Biological E held 200 million doses of its …

Rs 800 at Pvt Hosps, Rs 325 at Govt Centres: India's 1st Needle-free Nasal Vax, Now Available as Booster
1 year, 11 months ago

Rs 800 at Pvt Hosps, Rs 325 at Govt Centres: India's 1st Needle-free Nasal Vax, Now Available as Booster

News 18  

A single dose of Bharat Biotech’s intranasal vaccine iNCOVACC is now available on CoWin application for Rs 800, while Rs 325 has been fixed for purchase in government facilities. Provided that private hospitals are permitted to charge up to Rs 150 as an administrative charge for every dose of the Covid-19 vaccine, one dose of this vaccine developed on a …

Bharat Biotech’s nasal vaccine to be available as booster dose
2 years ago

Bharat Biotech’s nasal vaccine to be available as booster dose

The Hindu  

With the threat of COVID-19 resurfacing and India ramping up preventive health surveillance measures, Health Minister Mansukh Mandaviya said on Friday that a vaccine, which could be administered as nasal drops, would henceforth be available for public use. “We have made available a nasal vaccine, developed by Bharat Biotech, that can be used as a precaution dose. A spokesperson for …

COVID-19: Centre approves Bharat Biotech's intranasal vaccine, to be available on CoWIN
2 years ago

COVID-19: Centre approves Bharat Biotech's intranasal vaccine, to be available on CoWIN

Firstpost  

The needle-free vaccine will be available at private centres. It will be introduced on the Co-WIN platform on Friday evening New Delhi: Bharat Biotech’s intranasal COVID-19 vaccine has been approved by the Ministry of Health and Family Welfare for inclusion in the vaccination programme as a booster dose for those above 18 years of age, official sources said on Thursday. …

Indian Army issues advisory on Covid, asks defence personnel to take safety measures
2 years ago

Indian Army issues advisory on Covid, asks defence personnel to take safety measures

India TV News  

The Indian Army issued an advisory on Friday asking defence personnel to take up adequate measures to tackle COVID. The advisory asked them to take up measures such as the usage of face masks in closed or crowded places, practising hand sanitisation, and maintaining social distancing among others. Union Health Minister Dr Mansukh Mandaviya is set to hold a virtual …

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose
2 years ago

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose

News 18  

The Serum Institute of India has sought the drug regulator’s approval for market authorisation of its COVID-19 vaccine Covovax as a booster dose for those aged 18 years and above who have been administered two doses of Covishield or Covaxin, official sources said on Thursday. Prakash Kumar Singh, director, government and regulatory affairs, SII, submitted a market authorisation application for …

Bharat Biotech urges Centre to include its intranasal COVID vaccine in CoWIN portal
2 years ago

Bharat Biotech urges Centre to include its intranasal COVID vaccine in CoWIN portal

Deccan Chronicle  

Hyderabad: Bharat Biotech has requested the central government to include its intranasal COVID-19 vaccine iNCOVACC, in CoWIN portal to enable the recipients of the jab to get vaccination certificate. The company sources said Bharat Biotech is currently holding discussions with international “potential partners” who have approached the company for manufacturing and distribution of the intranasal vaccine globally. “Since iNCOVACC has …

Bharat Biotech misstated Covaxin trial data
2 years ago

Bharat Biotech misstated Covaxin trial data

Deccan Chronicle  

HYDERABAD: Extremely serious procedural leniencies and incorrect reporting of the results of trials of Covaxin, Bharat Biotech’s anti-Covid vaccine, have come to light, raising some very uncomfortable questions on the vaccine’s rollout for general use in India. Inquiries and investigation into the three phases of human trials of Covaxin have found grave reporting errors – some that appear to be …

Govt, Bharat Biotech Deny ‘Shortcut’ in Covaxin Trials: What's the Controversy?
2 years, 1 month ago

Govt, Bharat Biotech Deny ‘Shortcut’ in Covaxin Trials: What's the Controversy?

The Quint  

The allegations: Here's a quick run through of the STAT report. It said that Bharat Biotech: Omitted data of some participants in the phase 1 trial when the study was published in a medical journal. The report says they had access to internal documents from the company, and they also quote people in the company, including Krishna Mohan, one of …

50 million doses of Covaxin set to expire early 2023 due to poor offtake
2 years, 1 month ago

50 million doses of Covaxin set to expire early 2023 due to poor offtake

The Hindu  

Nearly 50 million doses of Bharat Biotech’s COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said. Due to lack of product demand, production stoppage of Covaxin - a two dose jab, was initiated by Bharat Biotech earlier this year, though the vaccine maker …

COVID: 50 million Covaxin doses set to expire early 2023 due to poor off take
2 years, 1 month ago

COVID: 50 million Covaxin doses set to expire early 2023 due to poor off take

India TV News  

Highlights Covaxin lying with the firm are set to expire early next year There are no takers owing to poor demand, said company sources India reported 1,082 fresh COVID-19 cases on Saturday Covaxin news: Nearly 50 million doses of Bharat Biotech’s COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers …

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report
2 years, 4 months ago

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report

Live Mint  

The government has approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin, news agency PTI has reported on 10 August citing official sources. "Corbevax will be considered as a precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of …

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients
2 years, 4 months ago

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients

News 18  

The Centre has approved Biological E’s Corbevax as a Covid-19 precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Union Health Secretary Rajesh Bhushan said, “Corbevax will be available as precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines …

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon
2 years, 4 months ago

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon

News 18  

The Union health ministry is expected to soon approve Biological E’s Corbevax as a precaution dose for people above 18 years who are double vaccinated with either Covishield or Covaxin, official sources said on Tuesday. “Corbevax will be considered as a precaution dose after completion of 6 months or 26 weeks from the date of administration of the second dose …

Adults may get different vaccine as booster shot instead of Covishield, Covaxin
2 years, 4 months ago

Adults may get different vaccine as booster shot instead of Covishield, Covaxin

Live Mint  

As the government has continued to emphasize Covid booster doses due to the rising number of cases, a panel has recommended a different vaccine for Indian adults. Government panel National Technical Advisory Group on Immunisation has recommended Biological E's Corbevax as a precaution dose for adults fully vaccinated with either Covishield or Covaxin. "Corbevax may be considered for a third/precaution …

India's Covid Vaccinations Hit 200 Crore Mark in Big Milestone for 7-Phase Drive Under Modi's Leadership
2 years, 5 months ago

India's Covid Vaccinations Hit 200 Crore Mark in Big Milestone for 7-Phase Drive Under Modi's Leadership

News 18  

India has crossed record 200 crore mark in Covid-19 vaccinations within 18 months of launching the inoculation exercise in January last year. #200CroreVaccinations https://t.co/FtobFYBprV— Dr Mansukh Mandaviya July 17, 2022 A seven-phase vaccination drive was followed on the principle of Prioritization for Vaccine Administration based on scientific advice and global best practices, government officials told News18. While some experts had …

AstraZeneca and Pfizer Vaccines Saved Over 1.2 Crore Lives in First Year: Study
2 years, 5 months ago

AstraZeneca and Pfizer Vaccines Saved Over 1.2 Crore Lives in First Year: Study

News 18  

The AstraZeneca and Pfizer COVID-19 vaccines saved over 1.2 crores lives, while India's indigenous Covaxin averted over 3.7 lakh deaths in the first year of the global immunisation campaign, according to a modelling study. Last month, a study on excess deaths from 185 countries and territories by the Imperial College London, UK, calculated that COVID-19 vaccines saved around 2 crore …

NTAGI Panel Recommends Use of Covid Vaccines Corbevax, Covaxin for Kids Aged 5-12 Years
2 years, 5 months ago

NTAGI Panel Recommends Use of Covid Vaccines Corbevax, Covaxin for Kids Aged 5-12 Years

News 18  

The NTAGI's Standing Technical Sub-Committee approved the use of COVID-19 vaccines Corbevax and Covaxin for children aged between five and 12 years, official sources said on Friday. Data of Biological E's Corbevax and Bharat Biotech's Covaxin for children aged between five and 12 years were reviewed in the STSC meeting held on June 16 and members decided that the vaccines …

Corbevax, Covaxin vacines get nod for use among 5-12 years olds; details here
2 years, 5 months ago

Corbevax, Covaxin vacines get nod for use among 5-12 years olds; details here

Live Mint  

Biological E's Corbevax and Bharat Biotech's Covaxin on July 8 received the nod from the National Technical Advisory Group on Immunisation's Standing Technical Sub-Committee for use among children aged between 5-12 years. The Drugs Controller General of India granted emergency use authorisation to the Biological E's Corbevax for 5-12 year old and Bharat Biotech's Covaxin for minors belonging to the …

Serum Institute gets govt nod to export 32.4 lakh doses of Covovax vaccine to US
2 years, 5 months ago

Serum Institute gets govt nod to export 32.4 lakh doses of Covovax vaccine to US

India Today  

The government has allowed Serum Institute of India to supply 32.4 lakh doses of its Covid-19 jab Covovax under the brand name Nuvaxovid to the US, which will be the first vaccine to be exported to the country by any Indian manufacturer, official sources said on Friday. "It is a matter of pride for us and our country that, in …

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI
2 years, 5 months ago

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI

The Hindu  

Allowing Biological E’s Corbevax as a booster for those fully vaccinated against COVID-19 with either Covishield or Covaxin is likely to be considered by the NTAGI, which is scheduled to meet on Tuesday, sources said. “The National Technical Advisory Group on Immunisation will discuss allowing Corbevax, which has been cleared by the DCGI, as a booster for those fully vaccinated …

Bharat Biotech Nasal Covid Vaccine's Phase 3 Trials Completed
2 years, 6 months ago

Bharat Biotech Nasal Covid Vaccine's Phase 3 Trials Completed

News 18  

Bharat Biotech on Saturday said that the clinical Phase III trials of the nasal vaccine for Covid-19 have been completed and that the company will submit its data with Drugs Controller General of India next month. Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech on Saturday said, if everything is okay, then they will get permission to launch …

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years: Bharat Biotech
2 years, 6 months ago

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years: Bharat Biotech

The Hindu  

Bharat Biotech International Limited, on Friday, announced that COVID-vaccine Covaxin has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study. The company in its press release said that Bharat Biotech had conducted phase II/III, open-label, and multi-centre study to evaluate the safety, reactogenicity, and immunogenicity Covaxin in healthy children and adolescents in 2-18 years …

Covaxin safe, well-tolerated in 2-18 years age-group, announces Bharat Biotech
2 years, 6 months ago

Covaxin safe, well-tolerated in 2-18 years age-group, announces Bharat Biotech

Firstpost  

The clinical trial conducted in the paediatric population between June 2021 to September 2021 has shown safety, less reactogenic, and robust immunogenicity Hyderabad: Bharat Biotech International Limited on Friday announced that its COVID-19 vaccine Covaxin has proven to be safe, well-tolerated and highly immunogenic in paediatric subjects in phase II/III study. Bharat Biotech had conducted phase II/III, open-label, and multi-centre …

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above
2 years, 6 months ago

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above

ABP News  

New Delhi: The Drug Controller General of India approved the Corbevax Covid-19 booster as heterologous Covid-19 booster dose for adults above the age of 18 years who got their primary Covid-19 vaccination of Covishield or Covaxin administered six months before, reported news agency ANI. Recently, BE has furnished its clinical trials data to the DCGI who after a detailed evaluation …

Germany recognises Bharat Biotech's Covaxin for travel from June 1
2 years, 6 months ago

Germany recognises Bharat Biotech's Covaxin for travel from June 1

India TV News  

Highlights WHO in November last year issued an emergency use listing for Covaxin The step added a growing portfolio of vaccines validated for the prevention of COVID-19 WHO's EUL procedure assesses the quality, safety and efficacy of COVID-19 vaccines Germany has recognised the WHO-listed Bharat Biotech's COVID vaccine Covaxin, for travel to the country starting June 1. World Health Organization …

Jabs for Kids, Reducing Gap Between Doses for Those Travelling Abroad on Agenda as NTAGI Meets Today
2 years, 7 months ago

Jabs for Kids, Reducing Gap Between Doses for Those Travelling Abroad on Agenda as NTAGI Meets Today

News 18  

As India witnesses a surge in coronavirus cases once again, the Covid-19 working group of the National Technical Advisory Group on Immunisation will meet at noon on Wednesday to discuss reducing the gap between the second dose and the precaution dose for people traveling abroad as well as vaccinations for 5-12 and 6-12 age groups. Last week, India’s drug regulator …

No Haste In Granting Emergency Use Authorization To Covaxin & Covishield: Supreme Court
2 years, 7 months ago

No Haste In Granting Emergency Use Authorization To Covaxin & Covishield: Supreme Court

Live Law  

In its judgment holding that the policy of the Union Government on COVID-19 vaccination policy is reasonable, the Supreme Court rejected the contention that restricted emergency use approvals had been granted to COVISHIELD and COVAXIN in haste, without thorough review of the relevant data.The court observed that the challenge to the procedures adopted by the expertbodies while granting. "However, it …

SEC seeks more data from Serum Institute of India over COVID vaccine 'Covovax' for 7-12 age group: Sources
2 years, 7 months ago

SEC seeks more data from Serum Institute of India over COVID vaccine 'Covovax' for 7-12 age group: Sources

India TV News  

Highlights DCGI subject expert committee on April 29 sought more data from SII on Covovax vaccine SEC has sought more data for Covovax vaccine for 7-12 years age group Covovax has already been recommended by DCGI for children above 12 years of age Coronavirus vaccine: The Drugs Controller General of India's subject expert committee on Friday sought more data from …

COVID-19: Govt to expedite process of recognition of Biological E Corbevax by other countries
2 years, 7 months ago

COVID-19: Govt to expedite process of recognition of Biological E Corbevax by other countries

The Hindu  

The government plans to expedite the process of recognition of COVID-19 vaccine Corbevax by other countries while its manufacturer Biological E pursues WHO's emergency use listing for the jab being administered in India among the 12-14 years age group. According to an internal document circulated to the members of the Empowered Group-5 on COVID-19 Vaccination, which will be meeting soon, …

In haste: The Hindu Editorial on vaccinating children against COVID-19
2 years, 7 months ago

In haste: The Hindu Editorial on vaccinating children against COVID-19

The Hindu  

The emergency use authorisation granted on April 26 to two COVID-19 vaccines — Corbevax for children 5-11 years, and Covaxin for children 6-11 years — is one more instance where the Indian drug regulator has acted in haste. Even if the EUA granted to Covaxin in January 2021 despite no safety and efficacy data of the phase-3 trial is condoned …

Discover Related